Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug delivery from ocular implants.

Tsutomu Yasukawa1, Yuichiro Ogura, Hideya Kimura

  • 1Department of Ophthalmology, Nagoya City University Medical School, Aichi 467-8601, Japan. yasukawa@kuhp.kyoto-u.ac.jp

Expert Opinion on Drug Delivery
|March 2, 2006
PubMed
Summary

Developing intraocular drug delivery systems (DDS) is crucial for treating eye diseases. Biodegradable implants show promise for sustained drug release, offering new hope for patients with serious vitreoretinal conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bleb Compressive Sutures in Descemet Stripping Automated Endothelial Keratoplasty for Eyes with Filtering Blebs Following Trabeculectomy.

Journal of clinical medicine·2026
Same author

Assessing the Validity of the Fellow Eye as an Internal Control in Early-Phase Clinical Trials for Myopic Chorioretinal Atrophy.

Journal of clinical medicine·2026
Same author

Multiple Evanescent White Dot Syndrome After mRNA COVID-19 Vaccination.

Cureus·2026
Same author

Comparison of Epiretinal Membrane Detection Rates Between Optos<sup>®</sup> and Clarus<sup>™</sup> Ultra-Widefield Fundus Imaging Systems.

Journal of clinical medicine·2026
Same author

Punctate Hyperfluorescent Spots on Indocyanine Green Angiography in Eyes with Central Serous Chorioretinopathy and Patient Demographics.

Journal of clinical medicine·2026
Same author

Intravitreal aflibercept 8 mg in patients from Japan with neovascular age-related macular degeneration: 48-week subgroup analysis of the PULSAR trial.

Japanese journal of ophthalmology·2025

Area of Science:

  • Ophthalmology
  • Biomaterials Science
  • Pharmacology

Background:

  • Vitreoretinal diseases are challenging to treat with conventional eye drops or systemic drugs.
  • Current methods fail to achieve adequate therapeutic drug concentrations within the vitreoretinal tissue.
  • There is a critical need for effective intraocular drug delivery systems (DDS).

Purpose of the Study:

  • To review the development and potential of intraocular drug delivery systems (DDS).
  • To highlight the advantages of sustained-release DDS for vitreoretinal diseases.
  • To discuss the progression from nonbiodegradable to biodegradable implantable DDS.

Main Methods:

  • Review of historical and current research on intraocular DDS.
  • Analysis of different implantable DDS designs (rods, plugs, discs, sheets).

Related Experiment Videos

  • Evaluation of biodegradable polymers in DDS formulation.

    • Main Results:

    • Nonbiodegradable implants were first used in 1996 for cytomegalovirus retinitis.
    • Biodegradable implants, utilizing various polymer types and shapes, have been extensively investigated.
    • An injectable rod formulation is currently in Phase III trials for macular edema.

    Conclusions:

    • Intraocular DDS offer a viable solution for delivering drugs to the posterior eye.
    • Biodegradable implants represent a significant advancement in sustained intraocular drug delivery.
    • Intraocular DDS using biodegradable implants may soon offer effective treatment for severe eye disorders.